Purinergic signaling (WP4900)

Homo sapiens

Purinergic signalling is involved in several processes including neurologic, endocrine, and immune system signalling.


Friederike Ehrhart and Egon Willighagen


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens



Pathway Ontology

nucleotide signaling via the purinergic P2Y receptors. nucleoside and nucleotide mediated signaling pathway


Label Type Compact URI Comment
5'-N-ethylcarboxamidoadenosine Metabolite pubchem.compound:3086599
AMP Metabolite chebi:16027
PSB 10 Metabolite pubchem.compound:10318703
PSB 36 Metabolite chemspider:9864310 1-butyl-8-(3- noradamantyl)-3-(3-hydroxypropyl)xanthine
CP-532,903 Metabolite pubchem.compound:10479002
SCH-58261 Metabolite pubchem.compound:176408
BAY 60–6583 Metabolite pubchem.compound:11717831
LPA Metabolite chebi:132742 Lysophosphatidic acid
SDZ WAG 994 Metabolite pubchem.compound:18755269
MRE3008F20 Metabolite pubchem.compound:5310960
UTP Metabolite chebi:15713
HEMADO Metabolite pubchem.compound:10981286 2-(1-Hexynyl)-N-methyladenosine
CVT-6883 Metabolite pubchem.compound:11270783
Adenosine Metabolite chebi:16335
ATL-146e Metabolite pubchem.compound:9805430
Caffeine Metabolite chebi:27732
UDP-glucose Metabolite chebi:46229
Istradefylline Metabolite pubchem.compound:5311037
8-Phenyl-1,3-dipropylxanthine Metabolite pubchem.compound:90477827
MRS-1754 Metabolite pubchem.compound:6603931
MRS-1220 Metabolite pubchem.compound:393595
MRS-1334 Metabolite pubchem.compound:10324445
CGS-21680 Metabolite pubchem.compound:3086599
DPCPX Metabolite chebi:73282 8-Cyclopentyl-1,3-dipropylxanthine
ZM-241,385 Metabolite pubchem.compound:176407
Regadenoson Metabolite pubchem.compound:219024
ATP Metabolite chebi:15422
GR 79236 Metabolite pubchem.compound:9884817
cAMP Metabolite chebi:17489
CPX Metabolite pubchem.compound:1917 8-Cyclopentyl-1,3-dimethylxanthine
2'-MeCCPA Metabolite pubchem.compound:122173097
PSB-0788 Metabolite pubchem.compound:44186581
MRS-3777 Metabolite pubchem.compound:11771279
MRS-1706 Metabolite pubchem.compound:5139184
Theophylline Metabolite chebi:28177
UDP Metabolite chebi:58223
IB-MECA Metabolite pubchem.compound:123683 CF-101
MRS-3558 Metabolite pubchem.compound:11248240
N-methyl-D-glucamine Metabolite chebi:59732
ADP Metabolite chebi:16761 
N6-Cyclopentyladenosine Metabolite pubchem.compound:657378
MRS-1523 Metabolite pubchem.compound:3661570
PSB-1115 Metabolite pubchem.compound:5311479
MRS-1191 Metabolite pubchem.compound:393594
CCPA Metabolite pubchem.compound:123807
SCH-442,416 Metabolite pubchem.compound:10668061
VUF-5574 Metabolite pubchem.compound:4046493
Gefapixant Metabolite pubchem.compound:24764487
Opiranserin Metabolite pubchem.compound:71566778
Ivermectin Metabolite pubchem.compound:9812710
Zn(2+) Metabolite chebi:29105
Suramin Metabolite pubchem.compound:5361
PPADS Metabolite pubchem.compound:6093163 pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid
L-Glutathione Metabolite chebi:16856
Ca(2+) Metabolite chebi:29108
Mg(2+) Metabolite chebi:18420
Cu(2+) Metabolite chebi:29036
Ca(2+) Metabolite chebi:29108
P2RY1 GeneProduct ensembl:ENSG00000169860
ADORA3 GeneProduct ensembl:ENSG00000282608
ADORA1 GeneProduct ensembl:ENSG00000163485
P2RY14 GeneProduct ensembl:ENSG00000174944
P2RY8 GeneProduct ensembl:ENSG00000182162
GNAT3 GeneProduct ensembl:ENSG00000214415
P2RX6 GeneProduct ensembl:ENSG00000099957
P2RX5 GeneProduct ensembl:ENSG00000083454
GNAI3 GeneProduct ensembl:ENSG00000065135
P2RY13 GeneProduct ensembl:ENSG00000181631
P2RY4 GeneProduct ensembl:ENSG00000186912
P2RX4 GeneProduct ensembl:ENSG00000135124
LPAR4 GeneProduct ensembl:ENSG00000147145 P2RY9
P2RY10 GeneProduct ensembl:ENSG00000078589
GNAO1 GeneProduct ensembl:ENSG00000087258
GNAI1 GeneProduct ensembl:ENSG00000127955
P2RY12 GeneProduct ensembl:ENSG00000169313
GNAT1 GeneProduct ensembl:ENSG00000114349
P2RX2 GeneProduct ensembl:ENSG00000187848
P2RY2 GeneProduct ensembl:ENSG00000175591
ADORA2B GeneProduct ensembl:ENSG00000170425
PANX1 GeneProduct ensembl:ENSG00000110218
GNAZ GeneProduct ensembl:ENSG00000128266
P2RX7 GeneProduct ensembl:ENSG00000089041
GNAT2 GeneProduct ensembl:ENSG00000134183
P2RX1 GeneProduct ensembl:ENSG00000108405
ADORA2A GeneProduct ensembl:ENSG00000128271
P2RY11 GeneProduct ensembl:ENSG00000244165
P2RY6 GeneProduct ensembl:ENSG00000171631
LPAR6 GeneProduct ensembl:ENSG00000139679
P2RX3 GeneProduct ensembl:ENSG00000109991
GNAS GeneProduct ensembl:ENSG00000087460 Gs alpha subunit (also Gαs, Gsα)
GNAI2 GeneProduct ensembl:ENSG00000114353


  1. 2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)--a high affinity agonist radioligand for A1 adenosine receptors. Klotz KN, Lohse MJ, Schwabe U, Cristalli G, Vittori S, Grifantini M. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6):679–83. PubMed Europe PMC Scholia
  2. Enhancement of esophageal carcinogenesis induced in rats by N-amyl-N-methylnitrosamine in the presence of 12-O-tetradecanoylphorbol-13-acetate. Matsufuji H, Ueo H, Mori M, Kuwano H, Sugimachi K. J Natl Cancer Inst. 1987 Nov;79(5):1123–9. PubMed Europe PMC Scholia
  3. Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. Martinson EA, Johnson RA, Wells JN. Mol Pharmacol. 1987 Mar;31(3):247–52. PubMed Europe PMC Scholia
  4. Adenosine receptors: development of selective agonists and antagonists. Daly JW, Jacobson KA, Ukena D. Prog Clin Biol Res. 1987;230:41–63. PubMed Europe PMC Scholia
  5. Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue. Williams M, Braunwalder A, Erickson TJ. Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):179–83. PubMed Europe PMC Scholia
  6. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, et al. J Pharmacol Exp Ther. 1996 Feb;276(2):398–404. PubMed Europe PMC Scholia
  7. Molecular physiology of P2X receptors. North RA. Physiol Rev. 2002 Oct;82(4):1013–67. PubMed Europe PMC Scholia
  8. Novel N6-substituted adenosine 5’-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2780-7. PubMed Europe PMC Scholia
  9. Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Zablocki JA, Wu L, Shryock J, Belardinelli L. Curr Top Med Chem. 2004;4(8):839–54. PubMed Europe PMC Scholia
  10. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Cerqueira MD. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D. PubMed Europe PMC Scholia
  11. A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential. Hutchinson SA, Scammells PJ. Curr Pharm Des. 2004;10(17):2021–39. PubMed Europe PMC Scholia
  12. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):405–13. PubMed Europe PMC Scholia
  13. Adenosine A2A receptors mediate GABAergic inhibition of respiration in immature rats. Mayer CA, Haxhiu MA, Martin RJ, Wilson CG. J Appl Physiol (1985). 2006 Jan;100(1):91–7. PubMed Europe PMC Scholia
  14. ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. Li Q, Ye K, Blad CC, den Dulk H, Brouwer J, Ijzerman AP, et al. J Pharmacol Exp Ther. 2007 Feb;320(2):637–45. PubMed Europe PMC Scholia
  15. Recent improvements in the development of A(2B) adenosine receptor agonists. Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D. Purinergic Signal. 2008 Dec;4(4):287–303. PubMed Europe PMC Scholia
  16. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. Froestl W, Muhs A, Pfeifer A. J Alzheimers Dis. 2012;32(4):793–887. PubMed Europe PMC Scholia
  17. Glutathione-Induced Calcium Shifts in Chick Retinal Glial Cells. Freitas HR, Ferraz G, Ferreira GC, Ribeiro-Resende VT, Chiarini LB, do Nascimento JLM, et al. PLoS One. 2016 Apr 14;11(4):e0153677. PubMed Europe PMC Scholia
  18. Glutathione induces GABA release through P2X7R activation on Müller glia. Freitas HR, Reis RA de M. Neurogenesis (Austin). 2017 Feb 6;4(1):e1283188. PubMed Europe PMC Scholia
  19. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Garceau D, Chauret N. Pulm Pharmacol Ther. 2019 Jun;56:56–62. PubMed Europe PMC Scholia
  20. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. Richards D, Gever JR, Ford AP, Fountain SJ. Br J Pharmacol. 2019 Jul;176(13):2279–91. PubMed Europe PMC Scholia
  21. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. Expert Opin Ther Pat. 2019 Dec;29(12):943–63. PubMed Europe PMC Scholia